182 related articles for article (PubMed ID: 23000905)
1. Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma.
Hollmig ST; Rieger KE; Henderson MT; West RB; Sundram UN
Am J Dermatopathol; 2013 Apr; 35(2):176-9. PubMed ID: 23000905
[TBL] [Abstract][Full Text] [Related]
2. LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.
Hanlon A; Stasko T; Christiansen D; Cyrus N; Galan A
Dermatol Surg; 2017 Mar; 43(3):431-436. PubMed ID: 28079637
[TBL] [Abstract][Full Text] [Related]
3. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker.
Hartel PH; Jackson J; Ducatman BS; Zhang P
J Cutan Pathol; 2006 Sep; 33 Suppl 2():24-8. PubMed ID: 16972949
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma.
Bull C; Mirzabeigi M; Laskin W; Dubina M; Traczyc T; Guitart J; Gerami P
J Cutan Pathol; 2011 Aug; 38(8):631-5. PubMed ID: 21623867
[TBL] [Abstract][Full Text] [Related]
5. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
6. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.
Soleymani T; Tyler Hollmig S
Curr Treat Options Oncol; 2017 Aug; 18(8):50. PubMed ID: 28762020
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
de Feraudy S; Mar N; McCalmont TH
Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
[TBL] [Abstract][Full Text] [Related]
8. Atypical fibroxanthoma.
Ziemer M
J Dtsch Dermatol Ges; 2012 Aug; 10(8):537-50. PubMed ID: 22709412
[TBL] [Abstract][Full Text] [Related]
9. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience.
McCoppin HH; Christiansen D; Stasko T; Washington C; Martinez JC; Brown MD; Zwald FO
Dermatol Surg; 2012 Feb; 38(2):230-9. PubMed ID: 22129349
[TBL] [Abstract][Full Text] [Related]
10. [Atypical fibroxanthoma and pleomorphic dermal sarcoma].
Ziemer M; Jäger IM; Dippel E
Hautarzt; 2019 Sep; 70(9):661-669. PubMed ID: 31468069
[TBL] [Abstract][Full Text] [Related]
11. Atypical fibroxanthoma with perineural or intraneural invasion: report of two cases.
Dettrick A; Strutton G
J Cutan Pathol; 2006 Apr; 33(4):318-22. PubMed ID: 16630185
[TBL] [Abstract][Full Text] [Related]
12. Atypical fibroxanthoma and malignant fibrous histiocytoma.
Withers AH; Brougham ND; Barber RM; Tan ST
J Plast Reconstr Aesthet Surg; 2011 Nov; 64(11):e273-8. PubMed ID: 21664889
[TBL] [Abstract][Full Text] [Related]
13. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma.
Miller K; Goodlad JR; Brenn T
Am J Surg Pathol; 2012 Sep; 36(9):1317-26. PubMed ID: 22510760
[TBL] [Abstract][Full Text] [Related]
14. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
Winchester D; Lehman J; Tello T; Chimato N; Hocker T; Kim S; Chang J; Markey J; Yom SS; Ryan W; Mully T; Hodge D; Otley C; Arron ST
J Am Acad Dermatol; 2018 Nov; 79(5):853-859. PubMed ID: 29787841
[TBL] [Abstract][Full Text] [Related]
15. Pleomorphic Dermal Sarcoma: A Clinical and Histopathologic Emulator of Atypical Fibroxanthoma, but Different Biologic Behavior.
Carletti M; Nguyen DA; Malouf P; Ingersoll Z; Hosler GA; Weis SE
HCA Healthc J Med; 2022; 3(5):299-304. PubMed ID: 37425251
[TBL] [Abstract][Full Text] [Related]
16. Atypical fibroxanthoma and pleomorphic dermal sarcoma: Is superficial infiltration in subcutaneous tissue acceptable in AFX?
van Midden D; Flucke UE; Amir AL; Bonenkamp JJ; Lubeek SFK; Blokx WAM
Ann Diagn Pathol; 2022 Jun; 58():151915. PubMed ID: 35276548
[TBL] [Abstract][Full Text] [Related]
17. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma.
Gleason BC; Calder KB; Cibull TL; Thomas AB; Billings SD; Morgan MB; Hiatt KM; Smoller BR
J Cutan Pathol; 2009 May; 36(5):543-7. PubMed ID: 19476522
[TBL] [Abstract][Full Text] [Related]
18. Atypical fibroxanthoma-a diagnosis of exclusion!
Tchernev G; Tronnier M; Ananiev J; Taneva T; Patterson JW; Gulubova M; Trafeli JP; Gegova A; Harrell M; Guarneri C; Wollina U; Cardoso JC; Kanazawa N; Zisova L; Forsea AM; Zouboulis CC
Wien Med Wochenschr; 2013 Aug; 163(15-16):380-6. PubMed ID: 23319144
[TBL] [Abstract][Full Text] [Related]
19. AFX: what we now know.
McCalmont TH
J Cutan Pathol; 2011 Nov; 38(11):853-6. PubMed ID: 21955311
[No Abstract] [Full Text] [Related]
20. Pleomorphic spindle cell dermal neoplasm with dot-like keratin reactivity: keratin-positive AFX or carcinoma?
Ellis R; Chase E; Barland A; Rajpara A; Fraga GR
J Cutan Pathol; 2015 Nov; 42(11):847-52. PubMed ID: 26041010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
